News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Jim Palma: Proud to have had our abstract accepted for presentation at the upcoming ASCO Annual Meeting
Photo from Jim Palma/LinkedIn
May 18, 2024, 03:50

Jim Palma: Proud to have had our abstract accepted for presentation at the upcoming ASCO Annual Meeting

Jim Palma, CEO at Target Cancer Foundation, shared on LinkedIn:

“Very proud and excited to have had our abstract accepted for presentation at the upcoming ASCO Annual Meeting! If you’re at ASCO, please be sure to stop by on Saturday, June 1 from 9:00 am – 12:00 pm CT to view our poster and learn more.”

Source: Jim Palma/LinkedIn

abstract accepted ASCO ASCO24 cancer Jim Palma OncoDaily Oncology TargetCancer Foundation
Special Coverage
Blog
Apr 22, 2025, 13:59
The systemic therapy options available for mCRPC - National Comprehensive Cancer Network
Science
Apr 22, 2025, 13:49
Joshua Brody: How to measure T-cell BYSTANDER tumor killing to prevent antigen escape after cancer immunotherapy
Blog
Apr 22, 2025, 13:34
Sampad Roy: A potential paradigm shift in breast cancer treatment
Blog
Apr 22, 2025, 13:19
IASLC Board of Directors Elections 2025: Spotlight on Undesignated Seat Candidates
Oncolibrary
Apr 22, 2025, 13:02
Trodelvy and Keytruda Achieve Breakthrough Results, Ushering in a New Era for ADCs in Breast Cancer
Radiotherapy
Apr 22, 2025, 12:05
Success Rate and Survival After Stereotactic Radiotherapy
OncoDaily Pulse
Apr 22, 2025, 11:13
New section on OncoDaily - A space that brings all career opportunities into one place
Oncolibrary
Apr 22, 2025, 11:10
DESTINY-Breast09 trial: Enhertu + Pertuzumab Improves PFS in First-Line HER2+ Metastatic Breast Cancer
Blog
Apr 22, 2025, 11:06
How immune cell baselines may predict CD22 therapy outcomes in Pediatric Cancer - NCI Center for Cancer Research
Blog
Apr 22, 2025, 10:57
Register for MASCC25 at the early bird rate - The Multinational Association of Supportive Care in Cancer
Blog
Apr 22, 2025, 10:51
Amol Akhade: Sacituzumab govitecan plus pembrolizumab shows PFS benefit in metastatic TNBC
Blog
Apr 22, 2025, 10:44
Jeff Hunnicutt: Highlands Oncology Group announces a partnership with Agamon Health